Validation of FGFR screening by uromonitor and therascreen in FFPE tissue in bladder cancer in the context of the clinical-pathological real-world registry study “Bladder BRIDGister”
Thorsten Ecke(Helios Hospital Bad Saarow), Ralph M. Wirtz(Siemens Healthcare (Germany)), F. Linden, Elke Veltrup(Siemens Healthcare (Germany)), Dimitri Barski(Lukaskrankenhaus), Paula Soares(i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto), Hugo Prazeres(Instituto Português de Oncologia de Coimbra Francisco Gentil), Frank Friedersdorff(Charité - Universitätsmedizin Berlin), Stefan Koch(Linköping University), N. Gagel, José Brás(Van Andel Institute), A. Gössl, Roland Hake, T. Otto(Lukaskrankenhaus), Sebastian Eidt(St. Elisabeth-Hospital Bochum), João Vinagre(i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto), Carolina Dias, Matthias May(Barmherzige Brüder Klinikum St. Elisabeth in Straubing), Robert Stöhr(Friedrich-Alexander-Universität Erlangen-Nürnberg), J. Roggisch, Anna Kravchuk, Lilli Sommerfeldt
Cited by 0
Related Papers
Diagnosis and management of dementia with Lewy bodies
|Neurology|2017|4.4k
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
|New England Journal of Medicine|2009|2.1k
Analysis of shared heritability in common disorders of the brain
|Science|2018|2k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
The mTOR Signalling Pathway in Human Cancer
|International Journal of Molecular Sciences|2012|831